A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib
Diffuse large B-cell lymphoma (DLBCL) is a molecularly heterogeneous disease consisting of different subtypes with varying clinical behaviors. For example, the activated B-cell-like (ABC) type of DLBCL has lower cure rates with traditional chemotherapy regimens. The molecular pathway promoting tumor...
Saved in:
| Main Authors: | Geoffrey Shouse, Miemie Thinn |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/5471368 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
by: Ying Huang, et al.
Published: (2012-01-01) -
Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
by: Justin T Low, et al.
Published: (2020-03-01) -
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
by: Steven Habbous, et al.
Published: (2020-10-01) -
Serum albumin predicts survival in Indian adult diffuse large B cell lymphoma patients in the rituximab era
by: Anshul Gupta, et al.
Published: (2019-01-01) -
Lenalidomide in Diffuse Large B-Cell Lymphomas
by: Annalisa Chiappella, et al.
Published: (2012-01-01)